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The debilitating zoonosis Chagas disease (CD) is caused by infection with the flagellate 
protozoan Trypanosoma cruzi. One century after its discovery, a curative agent remains 
elusive. Immune evasion by T. cruzi results in a poorly controlled infection in the host, which 
can end in either sudden death or a fatal chronic disease that often eventuates after years of an 
asymptomatic infection. Polyparasitism or mixed/concurrent infections occur more often than 
not and contribute to the high degree of variability observed across both disease progression 
and the success of therapeutic interventions. A thorough understanding of the effects of 
polyparasitism on CD is essential for improving the likelihood of containing, treating, and 
eventually eliminating CD. 
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The impact of Chagas disease 
Chagas disease (CD) in humans is caused by infection with the flagellate 
protozoanTrypanosoma cruzi. As a neglected disease, CD is associated with malnutrition, 
poverty, and inadequate sanitation 1 and 2. Poor living conditions in areas where CD is 
endemic allow the vector of T. cruzi, a triatomine insect, to infest housing, increasing 
transmission to both mammalian and non-mammalian hosts [3]. Education and vector control 
have helped contain the spread of infection; however, CD remains a debilitating zoonosis. It 
is the leading cause of death and morbidity in the Latin American and Caribbean 
regions1 and 4, with approximately 8 million people infected worldwide [5], more than 25 
million people at risk of infection, and approximately 15 000 resultant deaths each year [6]. 
 
The acute phase may be completely asymptomatic or may result in a plethora of 
symptoms 7 and 8 that may lead to death over a variable time period 7 and 9. A consequence 
of increased immigration worldwide is that areas with a previously low prevalence of CD, 
such as the USA, Japan, and Australia, now report a growing number of cases 10 and 11. 
Additionally, the ramifications of delayed onset of symptoms in chronic infections could be 
that in coming years we can expect infected individuals to show symptoms, adding strain to 
global health systems. Thus, to ensure the containment and proper treatment of CD, it is of 
utmost importance that clinicians in countries of nonendemicity are able to recognise CD 
symptoms. An emerging issue is that of polyparasitism, where concurrent infections with 
different strains of T. cruzi and/or other parasites may be associated with variances in 
virulence, drug sensitivity, organ predilection, and clinical outcome [12]. As such, this will 
clearly have an impact on the clinical management of CD and, accordingly, a comprehensive 
knowledge of the complexities arising from polyparasitism is crucial for effectively 
combatting CD. 
 
Diagnosis of T. cruzi infection 
The accurate diagnosis of T. cruzi infection is pivotal to the clinical management of CD. T. 
cruzi has a complex life cycle (Figure 1), and its ability to infect any nucleated cell 
complicates diagnosis [13]. The acute phase of infection is generally associated with parasites 
circulating throughout the bloodstream prior to migration into host organs. As such, infection 
is detectable via serology, haemoculture, PCR, or visualisation of the parasites in blood 
smears 5 and 14. Additionally, when symptomatic, the acute phase can manifest as signs 
specific to T. cruzi infection, such as unilateral periorbital swelling (known as Romana's 
sign), or ulcerative lesions at the site of inoculation (known as Chagoma). Alternatively and 
more commonly observed with the transmission of T. cruzivia modes other than through the 
insect vector, symptoms can be vague such as fatigue, fever, anorexia, diarrhoea, and 
vomiting [6]. 
 
The indeterminate phase of infection follows where parasites are not as readily seen 
circulating the bloodstream but rather sequester in host organs. In this phase, serology and/or 
histology are generally used for diagnosis because morphological changes of key organs are 
not yet detectable 6 and 15. Where CD is endemic, the choice among ELISA, indirect 
immunofluorescence (IIF), or indirect haemogluttination (IHA) for serological testing is 
based on availability 6, 15 and 16. Although PCR is highly sensitive, it is not recommended 
as a diagnostic tool for CD owing to the small sample sizes that are analysed. Parasite 
detection from organ biopsies are more successful during chronic infection when parasites 
sequester within organs; however, this technique is often impractical because biopsies are not 
always feasible [16]. The chronic phase of infection is characterised by the enlargement of 
key organs (i.e., splenomegaly, hepatomegaly, and cardiomegaly), where detection of 
morphological changes, histology, and serology are used for diagnosis 6, 15 and 17. 
Additionally, there have been reported cases where parasite DNA is not detected in chronic 
infections, and much debate remains as to whether chronic damage associated with CD is the 
direct result of the parasitic infection or the subsequent effect of a host autoimmune 
response 6 and 18. 
 
Limitations of detection methods 
There are clear limitations with the specificity and sensitivity of current serological 
techniques used for diagnosing T. cruzi infection. Additionally, the absence of a ‘gold 
standard’ test that reliably and consistently detects the presence of a T. cruzi infection makes 
the evaluation of current methods difficult [19]. Crossreactivity between T. 
cruziand Leishmania spp. is well documented and causes issues with detection 20 and 21. In 
Brazil, the sensitivity of ELISA kits was reported as 100%, but in Panama, assay sensitivity 
ranged between 75% and 100% [14]. In Brazil, these studies determined that with the 
inclusion of leishmaniasis cases, specificity ranged between 82.8% and 100%; however, 
when leishmaniasis cases were excluded, specificity ranged from 95.6% to 100%. Moreover, 
the false negatives and false positives associated with commercial kits used to confirm 
infection are a major concern to public health 6 and 16. 
 
There is a definite need for more specific and sensitive techniques to diagnose CD, enabling 
the prompt treatment of those infected and the efficient evaluation of therapeutic intervention. 
However, organ tropism and the discovery that the most prevalent T. cruzi genotype present 
within the bloodstream can differ from the strain found sequestered within organs (Figure 2) 
further complicate diagnosis [22]. Additionally, not all T. cruzi strains are associated with an 
observable parasitaemia and the implications of undetected infections threaten the 
containment and clinical management of CD. Improvements of techniques used to diagnose 
any form of polyparasitism are required, with mixed infections likely to pose the biggest 
threat to public health and treatment success 23 and 24. 
 
T. cruzi strains and genetic diversity 
A panel of experts recently redefined T. cruzi into six discrete typing units (DTUs), TcI–
TcVI, and a proposed seventh T. cruzi branch, referred to as Tcbat, based on genetic 
characteristics observed across strains [7]. Variability among strains and DTUs in terms of 
virulence, infectivity, tissue tropism (Box 1), progression of disease, and drug susceptibility, 
as well as particular geographical regions, virulence within different host species and 
transmission cycles within areas where CD is endemic has been well 
documented 7, 25 and 26. However, there is as yet no clear association between genetic 
variants of the parasite and these life history or epidemiological characteristics. Infectivity is 
highly variable, and in murine models infectivity of strains was found to be dependent on 
DTU and within DTUs, dependent on their area of isolation [27]. Preliminary studies found 
that in comparison to inoculation via intraperitoneal injection, infectivity of one 
representative of DTUs TcI and TcII via the oral route varied significantly with parasite 
genotype, number of parasites, inoculation volume, and developmental stages [28]; however, 
with the highly heterogeneous nature of these genotypes, further study is required. 
Additionally, there is evidence that particular strains that are poor at invading and infecting 
host cells display increased infectivity via the oral route [29], a route of infection that has 
become more significant in recent years [30]. Strains expressing high levels of gp90 
isoforms, a metacyclic stage-specific molecule that negatively regulates the invasion process, 
are poor at invading and infecting host target cells. However, additional studies found that 
when gp90 isoforms that are susceptible to peptic digestion are ingested [31] and come into 
contact with gastric juices, these strains become highly invasive to host target cells and cause 
oral outbreaks, which are linked to more severe disease 21 and 32. More alarmingly, oral 
transmission is thought to be more efficient than the natural mode of transmission, and with 
strains that are linked to orally transmitted cases showing a high level heterogeneity, further 
study is required [33]. 
 
 
 
 
 
 
 
 
 
 
Box 1. The significance of tissue tropism/favourable niches 
Trypanosomes display an apparent preference to infect and sequester within particular host 
organs. Whether this is true tissue tropism or whether it is simply the outcome of differential 
survival of the parasite in different tissues that it infects by chance is an open question. 
Although Trypanosoma cruzi has the capacity to infect any nucleated cell, particular cell 
types, including cardiac and skeletal muscle, enteric nerves, and adipocytes, are commonly 
associated with disease 26 and 59, and the question must be asked: what is it about these 
particular environments that encourage and support infection with particular strains of T. 
cruzi? Across Leishmaniaspecies, vast differences in the manifestation of disease are 
observed because of species-specific preferences for niches present within varying host 
organs [60]. In the case of Australian trypanosomes, two clades isolated from native wildlife 
displayed differential tissue distribution within infected hosts [61]. Additionally, two 
different genotypes within one of these clades showed varying abilities to infect rat skeletal 
muscle (L6), kidney epithelial cells (Vero), human ileocecal adenocarcinoma cells (HCT8), 
and a human monocytic cell line (THP1) that was differentiated into a macrophage-like cell 
(A. Botero et al., unpublished). Within these in vitro studies a clear preference for the 
infection of kidney epithelial cells was observed. The in vivooutcome of differing tissue 
tropism between strains of T. cruzi is the observation of variation in disease 
progression 60, 62 and 63. In a murine model using the Col1.7G2 clone and/or the JG strain 
of T. cruzi, organ tropism varied between single and mixed infections [63]; similarly, 
humans suffering from chronic infection had differential tropism [22]. Tissue tropism or 
favourable niches have the potential to have a significant effect on disease progression and 
the success of therapeutic interventions, yet its direct effects remain largely unknown. 
 
Resistance is an issue with the current treatment options for CD, Nifurtimox and 
Benznidazole, and TcI strains are more resistant to antitrypanosomal agents in mice than TcII 
and TcV strains [34]. Interestingly, Benznidazole resistance has been observed among natural 
populations of T. cruzi in the Amazon without prior exposure to the drug6 and 35; however, 
further information on drug resistance and susceptibilities is required as there is no exact 
correlation across DTUs. 
 
Within a number of geographical regions in South America, DTUs are linked to different 
transmission cycles, with TcI strains predominantly observed in sylvatic cycles and TcII 
strains prevailing in domestic cycles [36]. Genetic variability observed across DTUs and the 
ecosystem in which T. cruzi circulates within and outside the human host are key limitations 
to the treatment of CD and an impediment to drug discovery. Although the parasite genotype 
can affect drug susceptibilities and mixed infections can affect the success of drug 
interventions, many studies fail to consider the effect of parasite genotype in drug trials. 
Furthermore, the potential effect that host species has on the expression of parasite virulence 
and the outcome of infection in both laboratory induced and naturally occurring T. 
cruzi infection studies has been largely overlooked and requires further study. 
 
Limitations of drug treatments and clinical management of Chagas disease 
Neither Benznidazole nor Nifurtimox are effective at completely curing CD. Both 
compounds have shown promise by slowing disease progression and improving the health of 
infected individuals [37], with the efficacy of Benznidazole currently being reviewed in the 
Benznidazole Evaluation of Interrupting Trypanosomiasis (BENEFIT)[38]. However, 
because they are expensive, have problems with resistance, require lengthy treatments, and 
are poorly tolerated by patients, both compounds fall short of the WHO recommendations for 
an ideal treatment [39]. Furthermore, drug treatments are still not always readily accessible, 
and the social stigma attached to the disease means that many governments struggle to 
acknowledge an incidence of CD, where compound toxicity and lengthy treatment regimens 
ensure that prophylactic treatments in those vulnerable to infection are unmanageable. 
 
These issues have led to research focusing on drug development; yet, to date, a curative agent 
has not been generated, with few compounds progressing into clinical trials [40]. The 
question must be asked: is this due to the difficulties involved with determining drug 
efficacy, or is the complexity of the parasite–host relationship a major limiting factor in 
effective treatment? 
 
T. cruzi has demonstrated an innate ability to adapt, evading the host immune system. Even 
when considering host and parasite genotype, there is no clear understanding of why infection 
with the same strain of T. cruzi can result in such variable disease progression and treatment 
success [26]. Although it is difficult to correlate chronic phase cure rates to individual 
parasite strains, failure of treatments during acute infection in a clinical study might have 
resulted from strain-dependent variation in drug sensitivity [34]. Thus, a better understanding 
of parasite genetic diversity and the effects of polyparasitism is crucial to drug discovery. 
 
 
 
The complexity of polyparasitism 
Polyparasitism has been widely reported among humans, vectors, and other parasite 
reservoirs 41 and 42. Areas where CD is endemic are associated with poverty and 
malnutrition and known to harbour multiple strains of T. cruzi along with other opportunistic 
parasites 2 and 43. Coinfections with different strains of T. cruzi are of concern because they 
can affect host susceptibility to acquiring CD, can cause variability in disease progression 
following infection, and can alter host responsiveness to treatments 44 and 45 (Figure 2). 
Although concurrent infections appear to be the norm rather than an anomaly, the precise 
interactions between parasites within a mixed infection, either synergistic or competitive, 
remain largely unknown 44, 46, 47 and 48. Compared with single strain T. cruzi infections, 
mixed infections in BALB/c mice were able to trigger a response that attenuates the damage 
caused by inflammation and disease severity [49]. 
 
To date, there have been various investigations into the incidence of natural mixed infections 
involving different parasite species within areas where CD is endemic. A study of intestinal 
protozoan and helminth parasites in Colombia, for example, found that 10.4% of children 
under 10 years of age were infected with two parasite species, whereas 52.1% were infected 
with three or more species [50]. In the case of mixed infections with T. cruzi and various 
helminths, reports of decreased helminth-associated death rates and a decreased ability for 
those infected to clear helminth infection suggest that mixed infections can be mutually 
beneficial to the parasites, allowing an increased risk of transmission [51]. For instance, 
intracellular protozoans such as T. cruzi initiate a T helper 1 (Th1)-like immune response that 
results in the production of interleukin-12 (IL-12), interferon (IFN), interferon-γ (IFN-γ), and 
tumour necrosis factor-α (TNF-α), whereas helminths initiate a Th2-like response resulting in 
IL-4, IL-5, and IL-10 production [52]. The presence of a Th2 immune response in wild type 
mice contributes to the persistence of T. cruzi and exacerbates disease symptoms [53]. 
Additionally, induction of a Th1 response protected the susceptible BALB/c mouse strain 
against the challenge of infection from virulent parasite strains, whereas the induction of a 
Th2 immune response resulted in higher parasitaemia and mortality [54]. 
 
When polyparasitism is defined more broadly, it can include coinfection with viral pathogens, 
for example, with HIV. T. cruzi–HIV concurrent infections present a risk to public health as a 
recrudescence of parasitaemia is often observed due to the immunosuppressive nature of 
HIV [55]. Further understanding of T. cruzi–HIV infections will be beneficial, considering 
the increased morbidity and mortality, and longer periods of drug treatment compared with 
HIV infection alone [56]. 
 
In a mixed infection involving multiple strains of T. cruzi, treatment may do more harm than 
good, with the potential for a drug to successfully target one strain but in doing so alter the 
competitive suppression of virulence in a mixed strain infection, resulting in a host 
succumbing to the effects of the remaining strain [57]. In other scenarios, competition among 
strains for resources within a host is observed with a mixed infection[44]. This is thought to 
affect growth, reproduction, survival rate of the parasite, and the health of the host with 
multi-clonal population studies proving that natural selection favours the more virulent 
strain 57 and 58. The study of artificial mixed infections has shown that drug efficacy differs 
compared with single infections [45], but the direct effect of mixed infections on drug 
efficacy within a clinical setting has yet to be fully elucidated. 
Although it is desirable to have one drug able to target every DTU, the more we learn about 
the complexity of the parasite, the more unrealistic this seems. In addition, the ideal drug 
would not only need to show efficacy in clearing parasites from the bloodstream and organs 
in individuals suffering from the early stages of organ infiltration but also in individuals 
suffering from years of chronic damage. With different strains sequestering within varying 
organs, the reality is that combination therapies utilising drugs that exert their 
antitrypanosomal effects via differing modes of actions may hold the answer. 
 
Concluding remarks: the future for drug discovery 
Unfortunately, the overall complexity of the relationship between T. cruzi and its human host 
is a limitation to drug discovery. There are understandable frustrations with the slow pace of 
advances with drug discovery and the complications associated with determining compound 
efficacy and cure in a clinical environment. Adding to these hindrances is the fact that with 
every gain in knowledge, another question surfaces (Box 2). 
 
To date, parasite–host interactions have largely been explored in experimental mono-infected, 
murine models. Unfortunately, the correlation between drug efficacy in mice and humans is 
not strong, and thus there is a clear need for other in vivo models for determining drug 
efficacy. Additionally, teasing apart the complex interactions between multiple strains of T. 
cruzi within an individual human host is critical given that polyparasitism has the potential to 
significantly affect the direction of drug discovery efforts. 
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Box 2.  
Outstanding questions 
• Are we able to develop a better understanding of the variability observed across 
multiple strains of Trypanosoma cruzi? 
 
• To further elucidate host–parasite and parasite–parasite interactions, should 
studies focus on mixed infections? 
 
• How can we address the apparent disconnect between drug efficacy observed in 
rodent models and the lack of success in human clinical trials? 
 
• Are there alternative models of study that may allow us to develop a better 
understanding of alternative transmission routes? 
 
• Are there superior in vivo models (i.e., other than rodent models) available for 
determining drug efficacy that could provide an improved correlation to the 
success of therapeutic interventions in humans? 
 
• Do we fully understand how immunosuppressive diseases such as HIV and 
cytomegalovirus affect disease progression and reactivation? 
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Figure 1. The life cycle of Trypanosoma cruzi. The life cycle for T. cruzi is complex and involves an insect 
vector and a mammalian or non-mammalian host. Firstly, the triatomine insect takes up a blood meal (A) 
containing blood form trypomastigotes from an infected host. The parasites differentiate into epimastigotes (B) 
and enter the midgut of the triatomine (C) where they replicate via binary fission. In the hindgut, the parasites 
differentiate into infective metacyclic trypomastigotes, which are deposited in the faeces of a triatomine at the 
bite site (D). The metacyclic trypomastigotes enter the bloodstream of a host through the insect bite site or by 
the host accidentally rubbing contaminated faeces into the eye or abraded skin, and infect host cells (E), and 
subsequently differentiate into amastigotes (F), replicate via binary fission (G), differentiates back into 
trypomastigotes (H), and burst out of cells into the bloodstream (I) to either infect additional host cells (J) or be 
taken up in a blood meal by the insect vector (A). 
 
Figure 2. The possible effect of polyparasitism on the clinical outcome of Chagas disease. The clinical outcome 
of Chagas disease is dependent on the course of infection and both the availability and subsequent success of 
drug treatment. The course of infection may differ depending on variability in infectivity and pathogenicity 
observed across Trypanosoma cruzi strains, and although most of the damage from CD is observed in the heart, 
the bloodstream, and the intestine, the extent to which damage occurs is both host- and strain-dependent. 
Furthermore, the outcome of competitive interactions may be influenced by variable drug sensitivity between 
various strains of T. cruzi and/or immune effector mechanisms, which may be compromised by concurrent 
infections with gastrointestinal helminths or the immunosuppressive effect of cytomegalovirus or HIV infection. 
Variable sensitivity to different drugs A (Nifurtimox) and B (Benznidazole) may be observed depending on the 
strain of T. cruzi, tissue distribution, acute or chronic infection, and degree of inflammatory response. 
 
 
 
 
 
